Bristol-Myers Squibb

1Q Revenues: $5.3 billion (+5%)

1Q Earnings: $1.1 billion (+12%)

Comments: U.S. sales increased 6% to $3.5 billion in the quarter. International sales increased 2% to $1.8 billion. Growth in the quarter was led by Yervoy, which had sales of $154.0 million, Onglyza/Kombiglyze, up 99% to $161.0 million, Sprycel, up 34% to $231.0 million, Orencia, up 28% to $254 million, and Baraclude, up 18% to $325.0 million. R&D expenses decreased 3% to $909.0 million.